Atossa Genetics rallies on hopes for ForeCYTE

Shares of Atossa Genetics (ATOS) rally 20% premarket as the company submits a premarket 510(k) notification to the FDA for the ForeCYTE Breast Aspirator.

The company notes that the regulator usually makes a decision within 90 days.

The product will be re-launched upon clearance. (PR)

For reference on this story, see here and here.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs